Big Win for Lupin: US FDA Clears Rivaroxaban Oral Suspension for Young Patients

Lupin Limited, a global pharmaceutical leader, has gained a significant regulatory milestone with the United States Food and Drug Administration (US FDA) granting approval for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Oral Suspension, 1 mg/mL. This approval represents a key step in expanding Lupin’s portfolio in pediatric anticoagulant therapies.

Key Highlights of the Approval

The US FDA approval covers Lupin’s Rivaroxaban Oral Suspension, 1 mg/mL, shown to be bioequivalent to Janssen Pharmaceuticals’ Xarelto Oral Suspension of the same strength.

This formulation is intended primarily for treating venous thromboembolism (VTE) and reducing the recurrence risk of VTE in pediatric patients from birth up to less than 18 years.

The drug is also indicated for thromboprophylaxis in pediatric patients aged two years and above with congenital heart disease who have undergone the Fontan procedure.

Lupin will manufacture this product at its Chhatrapati Sambhajinagar facility in India, demonstrating the company’s robust manufacturing capabilities aligned to global standards.

According to recent market data, Rivaroxaban Oral Suspension holds an estimated annual US market size of around USD 11 million, highlighting its commercial significance.

Lupin’s approval adds to its growing presence in the US pharmaceutical market, backed by strong financial performance, including a 52.1% year-on-year net profit increase in recent quarters.

This product expands Lupin’s portfolio in cardiovascular and specialized therapies, strengthening its foothold in both branded and generic medicines.

Significance and Next Steps

This regulatory nod not only underpins Lupin’s continuous innovation in life-saving therapies but also reinforces its commitment to high unmet medical needs in pediatric care. The approval is expected to bolster Lupin's US market penetration and contribute to sustained revenue growth in the cardiovascular segment.

Sources: Lupin Ltd official announcements, US FDA, CNBC-TV18